<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852241</url>
  </required_header>
  <id_info>
    <org_study_id>CCF4</org_study_id>
    <nct_id>NCT00852241</nct_id>
  </id_info>
  <brief_title>Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy and longevity of the use of
      Restylane® and Perlane® in combination for the rejuvenation of the infraorbital hollows and
      to measure patient satisfaction with this treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to determine the efficacy and longevity of the use of Restylane® and Perlane® in combination for the rejuvenation of the infraorbital hollows and to measure patient satisfaction with this treatment</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Infraorbital Hollows</condition>
  <arm_group>
    <arm_group_label>Restalyne and Perlane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restalyne and Perlane</intervention_name>
    <description>One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.</description>
    <arm_group_label>Restalyne and Perlane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and older

          -  No significant medical illness

          -  Subjects with the willingness and ability to understand and provide informed consent

        Exclusion Criteria:

          -  Under 18 years of age

          -  Pregnancy or Lactation

          -  Subjects who have had previous surgical treatment of the lower eyelid area or
             previous use of filling agents in the under eye area

          -  Subjects with a known allergy to the components in Restylane® or Perlane®

          -  Subjects currently taking blood thinners or who have had chemotherapy or radiation
             within the last 6 months

          -  Subjects with liver/kidney disease or compromise or who are immunocompromised

          -  Subjects with a known susceptibility to keloid formation or hypertrophic scarring

          -  Subjects with an open, non-healing sore or infection near the site of injections

          -  Subjects who are unable to understand the protocol or to give informed consent

          -  Subjects with mental illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <lastchanged_date>January 15, 2010</lastchanged_date>
  <firstreceived_date>February 25, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Edward Galiczynski, DO</name_title>
    <organization>Cleveland Clinic</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
